Popular Target Proteins

Research and development of biopharmaceutical targets is currently experiencing explosive growth across multiple dimensions. In the field of cancer immunotherapy, CAR-T therapy is built on CD19/BCMA as its cornerstone and is rapidly expanding to solid tumor targets (such as MSLN and GD2); ADC drugs are fiercely competing around core targets such as HER2, TROP2, and B7-H3; and bispecific antibodies are setting new standards for first-line treatment through the PD-1/VEGF combination. Targeted therapies for autoimmune diseases are focused on CD19, TNF, and the JAK pathway, ushering in a new era of precise regulation of immune balance. Stem cell targets are achieving breakthroughs on two fronts—regenerative medicine (MSC aging regulation) and cancer stem cells (CDH3, CCR4)—providing new tools for tissue repair and cancer treatment. The antiviral field is shifting from viral proteins to host factors such as ACE2 and Furin, exploring broad-spectrum antiviral strategies. These six major target areas intersect and advance synergistically, collectively forming an innovation matrix that spans from basic research to clinical translation, providing a rich and robust resource of targets for precision medicine and next-generation drug development.